Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1/GIP agonist have reshaped the therapeutic management of type 2 diabetes by influencing international treatment guidelines and prescribing patterns, rather than influencing patient-level outcomes directly within the scope of this study. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.